# OnCo record belinda (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/belinda/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "belinda", "NCT03570892" ;
  schema:name "BELINDA"@en ;
  schema:description "The one second-line CAR-T trial that failed, a reminder that manufacturing time and trial design can erase a real effect."@en ;
  schema:url <https://onco.cc/trials/belinda/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03570892> ;
  onco:status "negative" ;
  onco:tag "lesson:trial-design" ;
  onco:phase "3" ;
  schema:startDate "2019-05-09" ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/trials/juliet/>, <https://onco.cc/trials/transcend-nhl-001/>, <https://onco.cc/ideas/lymphoma-ev-manufacturing-time-as-a-trial-endpoint/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/> .